https://wikimd.org/index.php?action=history&feed=atom&title=EtrasimodEtrasimod - Revision history2026-04-26T20:26:24ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Etrasimod&diff=5804584&oldid=prevPrab: CSV import2024-05-20T06:22:43Z<p>CSV import</p>
<p><b>New page</b></p><div>[[File:Etrasimod.svg|thumb|right]] '''Etrasimod''' is a selective [[sphingosine-1-phosphate receptor]] modulator that is being investigated for the treatment of various [[autoimmune diseases]]. It is designed to modulate the immune system by targeting specific receptors involved in the immune response.<br />
<br />
==Mechanism of Action==<br />
Etrasimod works by selectively modulating the [[sphingosine-1-phosphate receptor]] (S1P1). This receptor plays a crucial role in the regulation of lymphocyte egress from lymphoid tissues. By modulating S1P1, etrasimod can reduce the number of circulating lymphocytes, thereby diminishing the immune response that contributes to autoimmune diseases.<br />
<br />
==Clinical Development==<br />
Etrasimod is currently undergoing clinical trials for several autoimmune conditions, including [[ulcerative colitis]], [[Crohn's disease]], and [[atopic dermatitis]]. The drug has shown promise in early-phase trials, demonstrating efficacy in reducing disease activity and improving patient outcomes.<br />
<br />
===Ulcerative Colitis===<br />
In clinical trials for [[ulcerative colitis]], etrasimod has been shown to induce clinical remission and mucosal healing in patients with moderate to severe disease. The drug's ability to selectively target S1P1 allows for a focused immune modulation, which is beneficial in managing the chronic inflammation associated with ulcerative colitis.<br />
<br />
===Crohn's Disease===<br />
Etrasimod is also being evaluated for its efficacy in treating [[Crohn's disease]], another chronic inflammatory bowel disease. Preliminary results suggest that etrasimod may help reduce inflammation and maintain remission in patients with Crohn's disease.<br />
<br />
===Atopic Dermatitis===<br />
In addition to gastrointestinal diseases, etrasimod is being studied for its potential in treating [[atopic dermatitis]], a chronic inflammatory skin condition. The drug's immunomodulatory effects could help alleviate the symptoms of atopic dermatitis by reducing skin inflammation and improving barrier function.<br />
<br />
==Side Effects==<br />
The most common side effects reported in clinical trials of etrasimod include [[headache]], [[nausea]], and [[fatigue]]. These side effects are generally mild to moderate in severity. Serious adverse events are rare but can include [[bradycardia]] and [[macular edema]].<br />
<br />
==Future Directions==<br />
Ongoing research aims to further elucidate the long-term safety and efficacy of etrasimod in various autoimmune diseases. Additional studies are also exploring the potential of etrasimod in other inflammatory conditions and its use in combination with other therapies.<br />
<br />
==See Also==<br />
* [[Sphingosine-1-phosphate receptor]]<br />
* [[Autoimmune disease]]<br />
* [[Ulcerative colitis]]<br />
* [[Crohn's disease]]<br />
* [[Atopic dermatitis]]<br />
<br />
==References==<br />
{{Reflist}}<br />
<br />
[[Category:Immunology]]<br />
[[Category:Autoimmune diseases]]<br />
[[Category:Drugs]]<br />
[[Category:Experimental drugs]]<br />
<br />
{{medicine-stub}}</div>Prab